

P.O. Box 747  
Falls Church, Virginia 22040-0747  
Phone: (703) 205-8000  
Fax: (703) 205-8050  
(703) 698-8590 (GIV)

**Birch, Stewart, Kolasch & Birch, LLP**

# Fax

<b>To:</b>	Examiner Covington	<b>From:</b>	David R. Murphy (Reg #22.751)
<b>Fax:</b>	703 746 5318	<b>Date:</b>	12 June 2003
<b>Phone:</b>		<b>Pages:</b>	(including cover sheet) 12
<b>Your Ref.:</b>	App #09/846,259	<b>Our Ref.:</b>	0425-0819P
<b>Re:</b>	Our 10 June 2003 Conference	<b>CC:</b>	

☒ Urgent   ☒ For Review   ☒ Please Comment   ☒ Please Reply   ☐ Please Recycle

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution, or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited. If your receipt of this transmission is in error, please notify this firm immediately by collect call to (703) 205-8000, and send the original transmission to us by return mail at the address above.

**Comments:**

Thank you very much for telephoning our offices on 10 June 2003. It is our understanding, based on that conference, that if the application were amended as shown on the attached sheets that all outstanding issues would be resolved and that you would pass the case to issue. No prior art was discussed.

If our understanding is correct please so inform us by any means convenient to you. We reliably receive e-mail sent to mailroom@bskb.com.

As soon as we have your response we will contact our client, who will determine whether, and in what manner the application will be amended.


*David R. Murphy*

App # 09/846,259  
Dkt # 0425-0189P

What is claimed is:

(currently amended)

1. ~~A 1,4-substituted cyclic amine derivative represented by the~~  
~~compound of~~  
following formula (I):



(I)


wherein A, B, C, D, and T are the same or different from one another and each represents methine or nitrogen, provided that one and only one of them represents nitrogen;

the bond represented by the following formula:




represents a single or double bond;

Y and Z are the same or different from each other and each represents methine, nitrogen, a group represented by the following formula:



or a group represented by the following formula:



provided at least one of them represents nitrogen;

R<sup>1</sup> and R<sup>2</sup> are the same or different from each other and each represents

6-12-03

hydrogen, halogeno, hydroxy, lower alkylsulfonylaminoalkyl, lower halogenated-alkylsulfonylaminoalkyl, 2-pyrrolidinon-1-yl, 1-hydroxy-1-(methoxypyridyl)methyl, methoxypyridylcarbonyl, 1,3-propanesultum-2-yl, lower hydroxypiperidyl-carbonylalkyl, lower hydroxyalkylamidoalkyl, lower halogenated-alkylamidoalkyl, lower dihalogenatedalkylamidoalkyl, ~~lower heteroarylamidoalkyl~~, lower hydroxyalkylamidoalkyl, optionally substituted amino, nitro, lower alkyl, lower alkoxy, lower acyl, lower alkoxyalkoxy, cyano, lower alkylsulfonyl, sulfonylamido, hydroxy-lower alkyl, hydroxy-lower alkoxy, lower alkoxycarbonylamino, lower alkylsulfonylamino, N-lower alkylalkylsulfonylamino, lower acylamino, optionally substituted aminoalkyl, optionally N-substituted lower acylaminoalkyl, optionally substituted aryl, optionally substituted arylsulfonylamino, lower alkylsulfonyloxy, hydroxyiminomethyl, (2-pyrrolidon-1-yl)methyl, (2-piperidon-1-yl)methyl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroarylalkyl, cycloalkylcarbonylaminoalkyl, optionally substituted ureido, optionally substituted ureido-lower alkyl, succinimido, (succinimido-1-yl)-lower alkyl, amido, optionally substituted carbamoyl, optionally substituted carbamoyl-lower alkyl, optionally substituted thiocarbamoyl-lower alkyl, formyl, aromatic acyl, heteroarylcarbonyl, halogenated lower alkyl, (2-imidazolidinon-1-yl)methyl, (2,4-imidazolidinedion-3-yl)methyl, (2-oxazolidon-3-yl)methyl, (glutarimido-1-yl)methyl, optionally substituted heteroarylhydroxyalkyl, cyano-lower alkyl, 1-hydroxy lower cycloalkyl, (2,4-thiazolidinedion-3-yl)methyl, optionally substituted 4-piperidylmethyl, heteroarylacyl, pyrrolidinylcarbonyl-lower alkyl, optionally substituted aminosulfonylalkyl, carboxy-lower alkyl, or lower alkylamidoalkyl; or (alternatively R<sup>1</sup> and R<sup>2</sup> together may form optionally substituted alicycle) optionally substituted heterocycle or alkylenedioxy, provided


*Om*  
6-12-03

these rings may be substituted;

R<sup>3</sup> represents hydrogen, halogeno, lower alkyl, hydroxy, hydroxy-lower alkyl, lower alkoxy, formyl, optionally substituted aralkyloxy, hydroxy-lower alkoxy, optionally substituted sulfamoyl, or optionally N-substituted sulfamoyl-lower alkyl;

R<sup>4</sup> represents hydrogen, lower alkyl, hydroxy-lower alkyl, lower alkoxyalkyl, optionally aryl-substituted aryloxyalkyl, or optionally aryl-substituted aralkyloxyalkyl;

R<sup>5</sup> represents lower alkyl, lower acyl, lower alkoxycarbonyl, aromatic acyl, or a group represented by the following formula:



wherein Q<sup>1</sup> and Q<sup>2</sup> are both single bonds, or one of them is a single bond while the other represents oxygen, carbonyl, a group represented by -NHCO-, a group represented by -NHSO<sub>2</sub>-, or a group represented by >CH-R<sup>7</sup>, wherein R<sup>7</sup> represents hydroxy, lower alkyl or halogeno:

s represents 0 or an integer of 1 to 6; and

R<sup>6</sup> represents optionally substituted aryl, (optionally substituted heteroaryl,) (optionally substituted benzoheteroaryl) 1,4-benzodioxanyl, 1,3-benzodioxolyl, benzothiazolyl, or cyano;

n represents 1;


m represents 0 or an integer of 1 to 6; and

p represents an integer of 1 to 3,


or 4  
and pharmacologically acceptable salts thereof.

gmm  
6-12-03

- (currently amended)
2. ~~A 1,4-substituted cyclic amine derivative represented by the~~  
~~following formula:~~  
 compound of



wherein R represents a substituent of the formula:



wherein the bond represented by the following formula:



and  $R^1, R^2, R^3, R^4, R^5, Y, Z, m$ , and  $p$  are each as defined in claim 1, ~~and~~  
 pharmacologically acceptable salts thereof.

- (currently amended)
3. ~~The 1,4-substituted cyclic amine derivative as set forth in claim 1 or~~  
~~a pharmacologically acceptable salt thereof, wherein  $m$  is 0 and  $p$  is 2.~~  
 compound of

- (currently amended)
4. ~~The 1,4-substituted cyclic amine derivative as set forth in claim 1 or~~  
~~a pharmacologically acceptable salt thereof, wherein  $Y$  is methine and  $Z$  is~~  
 nitrogen.

gm  
6-12-03

(currently amended) compound of  
5. The 1,4-substituted cyclic amine derivative as set forth in claim 1

or a pharmacologically acceptable salt thereof, which is a compound selected from among the following ones:

(267)

1-{1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl}-7-methoxy-1,2,3,4-tetrahydroquinoline,

(268) 1-{1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl}-7-methoxy-1,2,3,4-tetrahydroquinoline,

(269) 1-{1-(4-cyanopropyl)piperidin-4-yl}-7-methoxy-1,2,3,4-tetrahydroquinoline,  
(270)

1-{1-[2-(2-thienyl)ethyl]piperidin-4-yl}-7-methoxy-1,2,3,4-tetrahydroquinoline,  
(271)

1-{1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl}-7,8-dimethoxy-1,2,3,4-tetrahydroquinoline,

(272) 1-{1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl}-7,8-methylenedioxy-1,2,3,4-tetrahydroquinoline,

(273) 1-{1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl}-7-methoxy-8-methyl-1,2,3,4-tetrahydroquinoline,

(274) 1-{1-[2-(4-fluorophenyl)-2-oxoethyl]piperidin-4-yl}-7-methoxy-1,2,3,4-tetrahydroquinoline,

(275) 1-{1-[2-(4-fluorophenyl)-2-hydroxyethyl]piperidin-4-yl}-7-methoxy-1,2,3,4-tetrahydroquinoline,

(276) 1-{1-[2-(4-fluorophenyl)-2-fluoroethyl]piperidin-4-yl}-7-methoxy-1,2,3,4-tetrahydroquinoline, and

(283) 5-{4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl}-5,6,7,8-tetrahydroisoquinoline.

gm  
6-12-03

(currently amended)

6. <sup>^</sup> A pharmaceutical composition comprising a therapeutically effective amount of the ~~1,4-substituted cyclic amine derivative or salt as set forth in claim 1~~ <sup>compound of</sup> or its salt <sup>^</sup> in combination with a pharmaceutically acceptable carrier.

(currently amended) and

7. <sup>^</sup> An agent for treating, ameliorating, and preventing diseases against which serotonin antagonism is efficacious, which ~~contains~~ <sup>contains</sup> as the active ingredient the ~~1,4-substituted cyclic amine derivative as set forth in claim 1 or a~~ <sup>compound of</sup> pharmacologically acceptable salt thereof.

(currently amended) and


8. <sup>^</sup> An agent for treating, ameliorating, and preventing spastic paralysis, which ~~contains~~ <sup>contains</sup> as the active ingredient the ~~1,4-substituted cyclic amine derivative as set forth in claim 1 or a~~ <sup>compound of</sup> pharmacologically acceptable salt thereof.

(currently amended) composition

9. <sup>^</sup> A muscle relaxant which contains as the active ingredient the ~~1,4-substituted cyclic amine derivative as set forth in claim 1 or a~~ <sup>an effective amount of the compound of</sup> in a mixture with a pharmacologically acceptable salt thereof.

(currently amended)


10. <sup>^</sup> A process for producing a ~~1,4-substituted cyclic amine derivative~~ <sup>compound of the</sup> represented by the following formula:



wherein the bond represented by the following formula:

John  
6-12-03


and A, B, C, D, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, n, and p are each as defined in claim 1, which comprises removing, if necessary, the protecting group from a 1,4-substituted cyclic amine derivative (IX) represented by the following formula:



wherein the bond represented by the following formula:

and A, B, C, D, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, n, and p are each as defined in claim 1; and Pr.G represents hydrogen or a protecting group, and then reacting the same with L-R<sup>5</sup> wherein R<sup>5</sup> is as defined in claim 1; and L represents a leaving group.

- (currently amended)
11. ~~A process for producing 1,4-substituted cyclic amine derivative (X),~~  
~~a compound of~~  
~~as set forth in claim 1, which comprises reacting a fused cyclic amine represented~~  
 by the following formula:




wherein the bond represented by the following formula:

and A, B, C, D, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and n are each as defined in claim 1 with a cyclic ketone (VIII) represented by the following formula:

om  
6-12-03






wherein  $R^4$ ,  $p$ , and Pr.G are each as defined in claim 1

in the presence of a reducing agent to thereby give a 1,4-substituted cyclic amine derivative (IX), removing, if necessary, the protecting group therefrom and further reacting the same with  $L-R^5$ .

*(currently amended)*  
 compound of the

12. ~~A 1,4-substituted cyclic amine derivative represented by the following formula:~~



wherein the bond represented by the following formula:



and A, B, C, D,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $n$ , and  $p$  are each as defined in claim 1, provided that the case where  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are all hydrogen atoms is excluded.

*(currently amended)*  
 antagonizing


13. ~~A method for treating a disease to which serotonin antagonism is efficacious, which comprises administering an effective dose of the 1,4-substituted cyclic amine derivative as set forth in claim 1, or a pharmacologically acceptable salt thereof, to a person in need of such treatment.~~  
*compound of*

*Open*  
 6-17-03

- (currently amended) compound of  
 14. ~~The 1,4-substituted cyclic amine derivative as set forth in claim 1, in~~  
 which the bond represented by the following formula in the formula (I):




is a single bond, represented by the formula (XXI):



or a pharmacologically acceptable salt thereof.

- (currently amended) compound of  
 15. ~~The 1,4-substituted cyclic amine derivative as set forth in claim 1, in~~  
 which m is 0 in the formula (I), represented by the formula (XXII):




or a pharmacologically acceptable salt thereof.

- (currently amended) compound of  
 16. ~~The 1,4-substituted cyclic amine derivative as set forth in Claim 1, in~~  
 which m is 1 to 6 in the formula (I) or a pharmacologically acceptable salt  
 thereof.

*John*  
 6-17-03

17. <sup>(currently amended)</sup> ~~A 1,4-substituted cyclic amine derivative represented by the formula~~ <sup>compound of</sup>

(XXIII):




or a pharmacologically acceptable salt thereof.

18. <sup>(currently amended)</sup> ~~The 1,4-substituted cyclic amine derivative as set forth in claim 1, in~~ <sup>compound of</sup>  
 which the bond represented by the following formula in the formula (I):



is a double bond, represented by the formula (XXIV):




or a pharmacologically acceptable salt thereof.

19. <sup>(currently amended)</sup> ~~The 1,4-substituted cyclic amine derivative as set forth in claim 1, in~~ <sup>compound of</sup>  
 which the T is nitrogen.

*Open*  
6-12-03

## ABSTRACT OF THE DISCLOSURE

A novel ~~1,4-substituted cyclic amine derivative represented by the~~  
~~compound of the~~  
following formula:



wherein A, B, C, D, T, Y, and Z represent each methine or nitrogen;  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ , and  $R^5$  represent each a substituent; n represents 0 or an integer of 1 to 3; m represents 0 or an integer of 1 to 6; and p represents an integer of 1 to 3; and pharmacologically acceptable salts thereof. The compound has a serotonin antagonism and is clinically useful as medicament, in particular, for treating, ameliorating and preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.

Jan  
6-12-03